June 26 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:
ALDEYRA THERAPEUTICS RECEIVES SPECIAL PROTOCOL ASSESSMENT AGREEMENT LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR ADX-2191 FOR THE TREATMENT OF PRIMARY VITREORETINAL LYMPHOMA
ALDEYRA THERAPEUTICS INC - CLINICAL TRIAL EXPECTED TO BEGIN IN SECOND HALF OF 2025
Source text: ID:nBw3SKSBLa
Further company coverage: ALDX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.